Amprologix Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A
- (In Progress)
- Latest Deal Amount
-
$6.71M
- Investors
-
6
Amprologix General Information
Description
Developer of antimicrobial-resistant drugs designed to combat drug-resistant infections. The company utilizes cutting-edge machine learning algorithms to improve antibiotic properties, including nasal decolonization of methicillin-resistant Staphylococcus aureus, pneumonia, and surface skin infections, enabling clients to combat the growing problem of antibiotic resistance.
Contact Information
Website
www.amprologix.comCorporate Office
- Derriford Research Facility
- Plymouth Science Park, Research Way
- Plymouth PL6 8BU
- England, United Kingdom
Corporate Office
- Derriford Research Facility
- Plymouth Science Park, Research Way
- Plymouth PL6 8BU
- England, United Kingdom
Amprologix Timeline
Amprologix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | $6.71M | In Progress | Generating Revenue | |||
| 6. Later Stage VC | 20-Oct-2025 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Oct-2025 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 02-Jun-2025 | Completed | Generating Revenue | |||
| 3. Grant | 01-Apr-2021 | Completed | Generating Revenue | |||
| 2. Corporate | 20-Sep-2018 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
Amprologix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 2,772,000 | $0.000013 | $0.06 | $0.06 | 1x | $0.06 | 1.83% |
Amprologix Patents
Amprologix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10273272-B2 | Antimicrobial peptides | Active | 04-Mar-2014 | ||
| EP-3114134-A1 | Novel antimicrobial peptides | Active | 04-Mar-2014 | ||
| EP-3114134-B1 | Novel antimicrobial peptides | Active | 04-Mar-2014 | ||
| US-20170204146-A1 | Novel antimicrobial peptides | Active | 04-Mar-2014 | ||
| US-20120308638-A1 | Antimicrobial peptides | Active | 17-Dec-2009 | C07K7/08 |
Amprologix Signals
Amprologix Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Plutus Investment Group | Family Office | Minority | ||
| Saudi Biotechnology Accelerator | Accelerator/Incubator | |||
| MassChallenge | Accelerator/Incubator | |||
| UK Research and Innovation | Government | |||
| Ingenza | VC-Backed Company | Minority |
Amprologix FAQs
-
When was Amprologix founded?
Amprologix was founded in 2018.
-
Where is Amprologix headquartered?
Amprologix is headquartered in Plymouth, United Kingdom.
-
What is the size of Amprologix?
Amprologix has 5 total employees.
-
What industry is Amprologix in?
Amprologix’s primary industry is Drug Discovery.
-
Is Amprologix a private or public company?
Amprologix is a Private company.
-
What is Amprologix’s current revenue?
The current revenue for Amprologix is .
-
How much funding has Amprologix raised over time?
Amprologix has raised $1.03M.
-
Who are Amprologix’s investors?
Plutus Investment Group, Saudi Biotechnology Accelerator, MassChallenge, UK Research and Innovation, and Ingenza are 5 of 6 investors who have invested in Amprologix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process